TNF-αinhibitors represent the most well-supported class of biologics; TNF-α plays a central role in keratinocyte apoptosis and inflammatory amplification, and multiple studies have demonstrated that etanercept or infliximab combined with systemic corticosteroids significantly shortens re-epithelialization time, reduces gastrointestinal bleeding, and does not increase infectious risk, with similarly favorable outcomes reported in ICI-related SJS/TEN (30–32). Here, TNF is linked to Schwartz-Jampel syndrome.